Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
24 10월 2023 - 8:30PM
Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS a
leading medical technology company focused on developing innovative
treatments for patients suffering from mild-to-moderate obstructive
sleep apnea (OSA) and snoring in adults, has signed a U.S.
nationwide distribution agreement with Lincare, a leading supplier
of in-home respiratory therapy products and services for
approximately 1.8 million patients.
The agreement follows the successful conclusion
of a distribution pilot with Lincare, and marks an important
milestone in Vivos’ strategy to engage with leading durable medical
equipment (DME) companies in the United States. Vivos has agreed
that Lincare will have a six-month exclusivity to distribute
certain designated Vivos devices.
Jeff Barnhard, CEO of Lincare, said, “We are
pleased to offer oral appliances as an alternative treatment to our
non-compliant CPAP patients. Finding the best solutions for our
sleep apnea patients has always been a high priority for Lincare.
We look forward to working alongside Vivos-trained
dentists.”
Kirk Huntsman, Chairman and CEO of Vivos,
stated, “Across the United States, hundreds of thousands of new
CPAP units are rented or sold through DME companies each month.
Lincare is one of the market leaders in this sector, and we are
pleased to join forces with them in this pioneering initiative. It
is well known that a sizable number of sleep apnea patients
discontinue CPAP usage in search of alternative treatment options.
This important collaboration between a national supplier of DME
like Lincare and an innovative oral appliance company like Vivos
will bring fresh solutions and relief to patients currently seeking
alternatives. Our pilot trial allowed both parties time to work
through the program logistics, including the development of a new
Vivos proprietary software to manage DME patients and scale to a
national level.”
Mr. Huntsman continued, “As we move forward, we
see these types of agreements as a key component in Vivos’ quest to
achieve positive cash flows over the next year. We are currently
focused on extending the scope of our efforts with Lincare to the
next five major markets, with additional markets to follow
according to a rollout schedule over the next 6-12
months.”
About Vivos Therapeutics,
Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a
medical technology company focused on developing and
commercializing innovative diagnostic and treatment methods for
patients suffering from breathing and sleep issues arising from
certain dentofacial abnormalities such as mild-to-moderate
obstructive sleep apnea (OSA) and snoring in adults. The Vivos
Method represents the first clinically effective nonsurgical,
noninvasive, nonpharmaceutical and cost-effective solution for
treating mild to moderate OSA. It has proven effective in
approximately 40,000 patients treated worldwide by more than 1,800
trained dentists.
The Vivos Method includes the Vivos Complete
Airway Repositioning and/or Expansion (CARE) appliance therapy and
associated protocols that alter the size, shape and position of the
soft tissues that comprise a patient’s upper airway and/or palate.
The Vivos Method opens airway space and may significantly reduce
symptoms and conditions associated with mild-to-moderate OSA, such
as lowering Apnea Hypopnea Index scores. Vivos also markets and
distributes SleepImage diagnostic technology under its VivoScore
program for home sleep testing in adults and children. The Vivos
Integrated Practice (VIP) program offers dentists training and
other value-added services in connection with using The Vivos
Method.
For more information, visit
www.vivos.com.
Cautionary Note Regarding
Forward-Looking Statements
This press release and statements of the
Company’s management made in connection therewith contain
“forward-looking statements” (as defined in Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) concerning future
events, particularly with respect to the public offering described
herein. Words such as “may”, “should”, “expects”, “projects,”
“intends”, “plans”, “believes”, “anticipates”, “hopes”,
“estimates”, “goal” and variations of such words and similar
expressions are intended to identify forward-looking statements.
These statements involve significant known and unknown risks and
are based upon several assumptions and estimates, which are
inherently subject to significant uncertainties and contingencies,
many of which are beyond Vivos’ control. Actual results (including,
without limitation, the results of Vivos’ collaboration with
Lincare and the anticipated impact on Vivos’ sales and results of
operations as described herein) may differ materially from those
expressed or implied by such forward-looking statements. Factors
that could cause actual results to differ materially include, but
are not limited to: (i) the risk that Vivos may be unable to
implement revenue, sales and marketing strategies that increase
revenues, (ii) risks associated with regulatory scrutiny of and
adverse publicity in the sleep apnea treatment sector; (iii) the
risk that Vivos may be unable to secure additional financings on
reasonable terms when needed, if at all and (iv) other risk factors
described in Vivos’ filings with the Securities and Exchange
Commission (“SEC”). Vivos’ filings can be obtained free of charge
on the SEC’s website at www.sec.gov. Except to the extent required
by law, Vivos expressly disclaims any obligations or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Vivos’
expectations with respect thereto or any change in events,
conditions, or circumstances on which any statement is
based.
Vivos Investor Relations
Contact: Julie Gannon Investor Relations
Officer 720-442-8113 jgannon@vivoslife.com
Vivos Therapeutics (NASDAQ:VVOS)
과거 데이터 주식 차트
부터 3월(3) 2025 으로 4월(4) 2025
Vivos Therapeutics (NASDAQ:VVOS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 4월(4) 2025